A detailed history of Great Valley Advisor Group, Inc. transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Great Valley Advisor Group, Inc. holds 18,250 shares of VRTX stock, worth $7.25 Million. This represents 0.22% of its overall portfolio holdings.

Number of Shares
18,250
Previous 14,787 23.42%
Holding current value
$7.25 Million
Previous $6.93 Million 22.47%
% of portfolio
0.22%
Previous 0.2%

Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$460.0 - $505.78 $1.59 Million - $1.75 Million
3,463 Added 23.42%
18,250 $8.49 Million
Q2 2024

Jul 16, 2024

BUY
$392.81 - $485.53 $773,050 - $955,523
1,968 Added 15.35%
14,787 $6.93 Million
Q1 2024

May 03, 2024

BUY
$407.69 - $446.08 $3.56 Million - $3.9 Million
8,737 Added 214.04%
12,819 $5.36 Million
Q4 2023

Feb 05, 2024

BUY
$343.0 - $410.68 $645,869 - $773,310
1,883 Added 85.63%
4,082 $1.66 Million
Q3 2023

Nov 06, 2023

BUY
$338.18 - $362.46 $200,878 - $215,301
594 Added 37.01%
2,199 $764,000
Q2 2023

Aug 10, 2023

SELL
$314.42 - $351.91 $314 - $351
-1 Reduced 0.06%
1,605 $564,000
Q1 2023

May 02, 2023

SELL
$283.23 - $323.1 $2.7 Million - $3.08 Million
-9,547 Reduced 85.6%
1,606 $506,000
Q4 2022

Jan 31, 2023

BUY
$285.76 - $321.48 $3.19 Million - $3.59 Million
11,153 New
11,153 $3.22 Million
Q3 2020

Oct 21, 2020

SELL
$255.65 - $303.1 $178,955 - $212,170
-700 Closed
0 $0
Q2 2020

Jul 31, 2020

BUY
$225.48 - $295.8 $157,836 - $207,060
700 New
700 $204,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $102B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Great Valley Advisor Group, Inc. Portfolio

Follow Great Valley Advisor Group, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Great Valley Advisor Group, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Great Valley Advisor Group, Inc. with notifications on news.